TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $28 to $32.
Stocks · News reference
Adaptive Biotechnologies Highlights NCCN Guideline Updates Naming clonoSEQ For MRD Assessment In Multiple Myeloma
Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journeyclonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity now
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27
Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $22 to $27.
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32
Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35
Goldman Sachs analyst Evie Koslosky initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announces Price Target of $35.